Share this article

Private equity firm Kohlberg and Abu Dhabi-based investor Mubadala have signed a definitive agreement to acquire a majority stake in PCI Pharma Services from Partners Group.

Under the deal, Kohlberg will obtain a majority stake, Mubadala a significant stake and Partners Group will retain a minority stake in PCI Pharma.

Partners Group is making the sale on behalf of its clients and along with its investment partners Thomas H Lee Partners and Frazier Healthcare Partners.

Financial details and size of the stakes remain undisclosed.

PCI Pharma provides pharmaceutical and biopharmaceutical global supply chain solutions from drug development through to commercial launch.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The company features global capabilities for drug development and manufacturing, clinical trials services and commercial packaging services. With 25 facilities across six countries, the company employs approximately 3,900 people globally.

PCI Pharma Services CEO Salim Haffar said: “Both Kohlberg and Mubadala’s experience and track record in supporting successful management teams will make a great impact on PCI’s continued journey of transformation as we focus on building capabilities to support the future demands of our biopharmaceutical customers in our shared goal of bringing life-changing therapies to patients worldwide.”

Kohlberg and Mubadala intend to work with PCl’s management team on the company’s growth and improving customer service experience, among others.

The partners will use growth trends in biologics and specialised drug therapies to boost capabilities such as sterile fill-finish of injectables, manufacturing and expansion into Asia and greater Europe.

Mubadala Pharma & Medtech head Camilla Macapili Languille said: “We have been particularly impressed by the quality and depth of PCI’s management team, as well as the company’s strong execution track record, impeccable values, and distinct vision for the long-term development of their business.

“We have strong conviction in the company’s growth trajectory and are committed to working with Kohlberg and Partners Group to ensure their long-term success.”